Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE). Issue 6 (June 2017)

• Record Type: Journal Article
• Authors: Cuomo, Rosario; Barbara, Giovanni; Annibale, Bruno
• Is Part Of: Digestive and liver disease. Volume 49:Issue 6(2017)
• Page Start: 595
• Page End: 603
• Publication Date: 2017-06
• Subjects: Diverticular disease -- Diverticulitis -- Position paper -- Rifaximin; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2017.01.164
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Management of diverticular disease has significantly improved in the last decade. Antibiotic treatment is used for symptom relief and prevention of complications. In Italy, the non-absorbable antibiotic rifaximin is one of the most frequently used drugs, and it is perceived as the reference drug to treat symptomatic diverticular disease. Its non-systemic absorption and high faecal concentrations have oriented rifaximin use to the gastrointestinal tract, where rifaximin exerts eubiotic effects representing an additional value to its antibiotic activity. This position paper was commissioned by the Italian Society of Gastroenterology governing board for a panel of experts (RC, GB, BA) to highlight the indications for treatment of diverticular disease. There is a lack of rationale for drug use for the primary prevention of diverticulitis in patients with diverticulosis; thus, rifaximin use should be avoided. The cyclic use of rifaximin, in association with high-fibre intake, is safe and useful for the treatment of symptomatic uncomplicated diverticular disease, even if the cost-efficacy of long-term treatment remains to be determined. The use of rifaximin in the prevention of diverticulitis recurrence is promising, but the low therapeutic advantage needs to be verified. No evidence is available on the efficacy of rifaximin treatment on acute uncomplicated diverticulitis.